Messenger RNA of FCGR3A and FCGR3B Genes as Monitoring Markers of Clear Cell Renal Adenocarcinoma (a Pilot Study)

Alyasova A.V., Amoev Z.V., Shkola O.O., Novikov D.V., Selivanova S.G., Novikov V.V.

Key words: monitoring renal cancer markers; mRNA of FCGR3A gene; mRNA of FCGR3B gene.

2022, volume 14, issue 3, page 22.

DOI: https://doi.org/10.17691/stm2022.14.3.03

Full text

html pdf

840

883

Abstract
References
How to cite

The aim of the study was to assess the capabilities of mRNA genes encoding CD16a (FCGR3A) and CD16b (FCGR3B) in tumor samples from patients with renal cancer, and characterize the tumor process in relation to clinical and morphological factors.

Materials and Methods. We used 125 tumor samples from patients with a histologically confirmed diagnosis of renal cancer T_1–4N_0–1M_0–1. A method described by Chomczynski and Sacchi was used to isolate nucleic acids. The mRNA levels were determined using a reverse transcription polymerase chain reaction and calculated according to ΔΔCt formula, taking into account the reaction efficiency.

Results. mRNA of the FCGR3A gene was detected in all tumor tissue samples under study; in contrast, mRNA of the FCGR3B gene was found only in 92.0% (115/125) of cases. In tumors classified as pT₁, the mRNA content of the FCGR3A gene was significantly lower than that in tumor samples of pT₃ size. There was the significant increase in the mRNA content of both genes with an increase in tumor grade, as well as in the cases with distant metastases. The presence of a tumor thrombus in the inferior vena cava system was accompanied by a significant increase in the mRNA content of the FCGR3A gene.

Conclusion. In tumor tissue samples from patients with clear cell renal cancer, the predominant production of the FCGR3A mRNA was observed in comparison with the FCGR3B mRNA. The revealed relationship of an increased amount of the FCGR3A mRNA and, in some cases, the FCGR3B mRNA with a number of clinical and morphological factors enables to consider the mRNA level of the genes as new monitoring biomarkers.

Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7–30, https://doi.org/10.3322/caac.21442.
Barata P.C., Rini B.I. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017; 67(6): 507–524, https://doi.org/10.3322/caac.21411.
Zhang S., Zhang E., Long J., Hu Z., Peng J., Liu L., Tang F., Li L., Ouyang Y., Zeng Z. Immune infiltration in renal cell carcinoma. Cancer Sci 2019; 110(5): 1564–1572, https://doi.org/10.1111/cas.13996.
Giraldo N.A., Becht E., Vano Y., Sautès-Fridman C., Fridman W.H. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015; 467(2): 127–135, https://doi.org/10.1007/s00428-015-1787-7.
Gillis C., Gouel-Chèron A., Jönsson F., Bruhns P. Contribution of human FcγRs to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 2014; 5: 254, https://doi.org/10.3389/fimmu.2014.00254.
Wang E., Adams S., Stroncek D.F., Marincola F.M. Human leukocyte antigen and human neutrophil antigen systems. In: Hematology. Silberstein L.E., Anastasi J., Hoffman R., Benz E.J., Heslop H., Weitz J. (editors). Elsevier; 2018: p. 1721–1737, https://doi.org/10.1016/b978-0-323-35762-3.00113-x.
Bhatnagar N., Ahmad F., Hong H.S., Eberhard J., Lu I.N., Ballmaier M., Schmidt R.E., Jacobs R., Meyer-Olson D. FcγRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcγRII (CD32). Eur J Immunol 2014; 44(11): 3368–3379, https://doi.org/10.1002/eji.201444515.
Chomczynski P., Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. Nat Protoc 2006; 1(2): 581–585, https://doi.org/10.1038/nprot.2006.83.
Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25(4): 402–408, https://doi.org/10.1006/meth.2001.1262.
Krasnogorova N.V., Novikov D.V., Fomina S.G., Alyasova A.V., Magomedov M.A., Novikov V.V., Karaulov A.V. The CD16a and CD16b mRNA level as potential immunological marker in colorectal cancer. Bulleten' sibirskoj mediciny 2019; 18(1): 220–227, https://doi.org/10.20538/1682-0363-2019-1-220-227.
Klein S.L., Flanagan K.L. Sex differences in immune responses. Nat Rev Immunol 2016; 16(10): 626–638, https://doi.org/10.1038/nri.2016.90.
Goloviznin M.V. Intervention of cancer cells in the processes of maturation and selection of T-lymphocytes as a factor in tumor progression. Immunologia 2001; 6: 4–10.
Davydov M.I., Matveev V.В., Polotsky В.Е., Matveev B.P., Nosov D.A. Surgical treatment of renal carcinoma metastases to the lungs. Rossijskij onkologiceskij zurnal 2003; 4: 15–18.
Serena G., Gonzalez J., Gaynor J.J., Salerno T., Verzaro R., Ciancio G. Pulmonary tumor embolization as early manifestation in patients with renal cell carcinoma and tumor thrombus: perioperative management and outcomes. J Card Surg 2019; 34(10): 1018–1023, https://doi.org/10.1111/jocs.14182.
Manso M., Pacheco-Figueiredo L., Santos-Silva A., Silva J., Silva C., Cruz F. Renal cell carcinoma with venous thrombus: should surgery be offered when metastasis is present at diagnosis? Urol Int 2018; 101(4): 387–390, https://doi.org/10.1159/000493510.
Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503–510, https://doi.org/10.1038/ni1582.
Campbell K.S., Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 2013; 132(3): 536–544, https://doi.org/10.1016/j.jaci.2013.07.006.
Wang W., Erbe A.K., Hank J.A., Morris Z.S., Sondel P.M. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 2015; 6: 368, https://doi.org/10.3389/fimmu.2015.00368.
Hakimi A.A., Voss M.H., Kuo F., Sanchez A., Liu M., Nixon B.G., Vuong L., Ostrovnaya I., Chen Y.B., Reuter V., Riaz N., Cheng Y., Patel P., Marker M., Reising A., Li M.O., Chan T.A., Motzer R.J. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer — data from a randomized phase III trial. Cancer Discov 2019; 9(4): 510–525, https://doi.org/10.1158/2159-8290.cd-18-0957.
Díaz-Montero C.M., Rini B.I., Finke J.H. The immunology of renal cell carcinoma. Nat Rev Nephrol 2020; 16(12): 721–735, https://doi.org/10.1038/s41581-020-0316-3.
Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3): 162–174, https://doi.org/10.1038/nri2506.
Guan Y., Chambers C.B., Tabatabai T., Hatley H., Delfino K.R., Robinson K., Alanee S.R., Ran S., Torry D.S., Wilber A. Renal cell tumors convert natural killer cells to a proangiogenic phenotype. Oncotarget 2020; 11(26): 2571–2585, https://doi.org/10.18632/oncotarget.27654.
Schleypen J.S., Baur N., Kammerer R., Nelson P.J., Rohrmann K., Gröne E.F., Hohenfellner M., Haferkamp A., Pohla H., Schendel D.J., Falk C.S., Noessner E. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12(3 Pt 1): 718–725, https://doi.org/10.1158/1078-0432.ccr-05-0857.
Xu W., Jiang X., Guan C., Gu M. The prognostic and predictive value of tumor infiltrating macrophage and neutrophil in patient with clear cell renal cell carcinoma: tumor infiltrating lymphocytes in renal cell carcinoma. Medicine (Baltimore) 2020; 99(46): e23181, https://doi.org/10.1097/md.0000000000023181.

Alyasova A.V., Amoev Z.V., Shkola O.O., Novikov D.V., Selivanova S.G., Novikov V.V. Messenger RNA of FCGR3A and FCGR3B Genes as Monitoring Markers of Clear Cell Renal Adenocarcinoma (a Pilot Study). Sovremennye tehnologii v medicine 2022; 14(3): 22, https://doi.org/10.17691/stm2022.14.3.03